Roquette acquires Crest Cellulose, expanding global reach of plant-based excipients portfolio
Roquette has completed its acquisition of India-based excipient manufacturer Crest Cellulose to continue realizing its strong growth ambitions and meet rising global demand for high-quality plant-based excipients.
Workers in lab. Image courtesy of Roquette.
Roquette (La Madeleine, France) has completed its acquisition of India-based excipient manufacturer Crest Cellulose to continue realizing its strong growth ambitions and meet rising global demand for high-quality plant-based excipients. All excipients produced at the facility—Microcel microcrystalline cellulose, Lycatab CT partially pregelatinized starch, and Roquette magnesium stearate—adhere to Roquette’s rigorous quality standards and all major international regulatory requirements.
“At Roquette, we believe true innovation can only be achieved in an environment where ingredient safety is completely assured,” said Paul Smaltz, vice president of Roquette Pharma Solutions, in a press release. “There’s no room for compromise or short cuts when tackling the world’s greatest health challenges. The team at Crest Cellulose share our conviction that quality is king, always striving to optimize processes and redefine what’s possible in drug delivery. As a global leader in health and nutrition, we’re excited to harness our newly expanded capabilities to support our network of customers and partners in India, Asia and the rest of the world.”
Crest Cellulose recently become the latest recipient of the Greentech “Environmental Protection” award, which gives Roquette an opportunity to expand its reach of sustainable development initiatives, Smaltz said. “For Crest Cellulose and its customers, this means sustainable development will become central to every operation, ensuring we deliver top quality solutions that champion people, the planet and prosperity,” he said. “Supporting our commitment to reducing greenhouse gas emissions* by 25% between 2021 and 2030, plans are in motion to install an additional 0.5-megawatt solar panel to the 10 kilowatts already in place at the site. This investment is designed to provide renewable energy for decades to come.”
(*) direct emissions produced by the company (scope 1) and indirect emissions related to the energy purchased and consumed by the company (scope 2).
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
